NCT07234591 A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
| NCT ID | NCT07234591 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Usynova Pharmaceuticals Ltd. |
| Condition | Plaque Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-10-21 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2025-10-21 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
Eligibility Criteria
Inclusion Criteria: * Male and female, ages 18 to 70 years * Body weight \>40 kg, body mass index (BMI) of 18 to 40 kg/m2 * Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit * Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception. Exclusion Criteria: * Diagnosed with non-plaque psoriasis * Previously received tyrosine kinase 2 (TYK2) inhibitors * Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects * Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials; * Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint infections within 6 months before screening, and other acute infectious diseases. * Has known or suspected skin or systemic autoimmune diseases other than psoriasis and psoriatic arthritis; * Other conditions that the investigator deems unsuitable for participation in this study. Other protocol defined inclusion/exclusion criteria could apply
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07234591 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Plaque Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07234591 currently recruiting?
Yes, NCT07234591 is actively recruiting participants. Contact the research team at yang_zhang@usynova.com for enrollment information.
Where is the NCT07234591 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07234591 clinical trial?
NCT07234591 is sponsored by Usynova Pharmaceuticals Ltd.. The trial plans to enroll 140 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.